ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Development

AlloVir and Baylor to make donor-derived T cell therapies that target coronaviruses

by Ryan Cross
March 27, 2020 | APPEARED IN VOLUME 98, ISSUE 12

 

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

The cell therapy company AlloVir and Baylor College of Medicine will expand their partnership to make cell therapies for people infected with or at high risk of infection from the novel coronavirus. The team plans to isolate T cells from the blood of people who recovered from COVID-19, the resulting disease. It will grow more of the T cells that attack the virus and keep them on hand for an allogeneic—also called off-the-shelf—cell therapy. The team tested a similar approach for preventing or treating other viral infections.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment